期刊文献+

对克罗恩病维持缓解的随访 被引量:1

下载PDF
导出
摘要 克罗恩病(Crohn’s disease,CD)是肠道慢性炎症性疾病,在整个胃肠道的任何部位均可发生,病程多迁延,活动期和缓解期相互交替出现。很多研究表明5-氨基水杨酸类药物(5-ASA,商品名:美沙拉嗪)治疗轻到中度的活动性克罗恩病有效,但至今关于美沙拉嗪用于维持缓解对预防CD的复发是否有确定的疗效仍存在争议。为此,本文对该病诊治及维持缓解进行了探讨。
作者 蒋楠 蔡建庭
出处 《浙江医学》 CAS 2008年第3期236-237,共2页 Zhejiang Medical Journal
  • 相关文献

参考文献10

  • 1Kamm M A. Debate: should mesalamine be used in Crohn's disease:comments and conclusions[J]. Infiamm Bowel Dis, 2005, 11(6):616-617.
  • 2Thomson A B R (International Mesalazine Study Group). Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease [J]. Aliment Pharmacol Ther, 1990.4:55-64.
  • 3Prantera C, Pallone F, Brunetti, et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease [J]. Gastroenterology, 1992, 103:363-368.
  • 4Thomson A B. Mesalazine (Mesasal/Claversal) 1.5g bd vs placebo in the maintenance of remission of patients with Crohn's disease[J]. Aliment Pharmacol Ther, 1995, 9:673-683.
  • 5Sutherland L R, Martin F, Bailey R J, et al. A randomized, placebo controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group[J]. Gastroenterology, 1997, 112:1069-1077.
  • 6Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis[J]. Am J Gastroenterol, 1994, 89:692- 698.
  • 7Steinhart A H, Hemphill D, Greenberg G R, et al. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis[J]. Am J Gastroenterol, 1994, 89:2116-2124.
  • 8Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables[J]. Gastroenterology, 1997, 113:1465-1473.
  • 9Carter M J, Lobo A J, Travis S P, et al. Guidelines for the management of inflammatory bowel disease in adults[J]. Gut, 2004, 53(Suppl 5):V1-16.
  • 10Juillerat P, Felley C, Mottet, et al. Drug safety in the treatment of Crohn's disease[J]. Digestion, 2005, 71(1):8-12.

同被引文献15

  • 1Carter M J,Lobo A J,Travis S P L.Guidelines for the management of inflammatory bowel disease in adults[J].Gut,2004,53(Suppl 5):V1-16.
  • 2Reddy S I,Friedman S,Telford J J,et al.Are patients with inflammatory bowel disease receiving optimal care[J]?Am J Gastroenterol,2005,100(6):1357-1361.
  • 3Sutherland L,Macdonald J K.Oral 5-aminosalicylic acid for indu cing remission in ulcerative colitis[J].Cochrane Database Syst Rev,2006,2:CD000544.
  • 4Hanauer S B,Stromberg U.Oral Pentasa in the treatment of active Crohn's disease:a meta-analysis of doubleblind,placebocontrolled trials[J].Clin Gastroenterol Hepatol,2004,2:379-388.
  • 5Weinshilboum R.Inheritance and drug response[J].N Engl J Med,2003,348(6):529-537.
  • 6Regueiro M,Loftus EV Jr,Steinhart A H,et al.Medical management of left-sided ulcerative colitis and ulcerative proctitis:critical evaluation of therapeutic trials[J].Inflamm Bowel Dis,2006,12(10):979-994.
  • 7Cohen R D,Woseth D M,Thisted R A,et al.A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis[J].Am J Gastroenterol,2000,95:1263-1276.
  • 8Ho G T,Chiam P,Drummond H,et al.The efficacy of corticosteroid therapy in inflammatory bowel disease:analysis of a 5-year UK inception cohort[J].Aliment Pharmacol Ther,2006,24(2):319-330.
  • 9Tung J,Loftus EV Jr,Freese D K,et al.A populalion-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis[J].Inflamm Bowel Dis,2006,12(12):1093-1100.
  • 10Fraser A G,Orchard T R,Jewell D P.The efficacy of azathioprine for the treatment of inflammatory bowel disease:a 30 year review[J].Gut,2002,50(4):485-489.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部